Table 1 Patient characteristics

Location

North America

30

58.8

Europe

18

35.3

Australia

3

5.9

Age

2–4 years

3

6

5–9 years

13

25

10–17 years

31

61

18–21 years

4

8

Sex

Male

30

59

Female

21

41

Down syndrome

Yes

4

8

No

47

92

Cytogenetic subtype

ETV6-RUNX1

5

10

Hyperdiploid

4

8

Ph-like

4

8

Ph-positive

3

6

Hypodiploid

3

6

TCF3-PBX1

2

4

KMT2A-rearranged

1

2

t(17;19)

1

2

iAMP21

1

2

NOS

19

37

Unknown

8

16

Indication for InO

First relapse (refractory)

10

20

Second relapse

22

43

Third relapse

10

20

Forth relapse

6

12

Fifth relapse

2

4

Primary refractory

1

2

Refractory to preceding regimen

Yes

41

80

No

9

18

Unknown

1

2

Number of prior treatment regimens (excluding HSCT)

2–3

8

16

4–6

28

55

≥7

15

29

Prior HSCT

None

29

57

1

18

35

2

3

6

3

1

2

Prior CD19-directed therapy

Blinatumomab

22

43

CD19 CAR T-cells

15

29

Both of the above

3

6

None

11

22

Prior CD22-directed therapy

Moxetumomab

6

12

CD 22 CAR T-cells

3

6

Both of the above

1

2

InO

1

2

None

40

78

Bone marrow status

M1, MRD positive

8

16

M2

4

8

M3

38

75

Unknown

1

1

Extramedullary disease

Yes

2

4

No

49

96